Cutler Group’s Zevra Therapeutics ZVRA Stock Holding History

Cutler Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-679	Closed	-$3K	–	4870
2022 Q4	$3K	Sell	679 -1,400	-67%	-$7.11K	﹤0.01%	3573
2022 Q3	$12K	Sell	2,079 -2,767	-57%	-$15.7K	﹤0.01%	3026
2022 Q2	$21K	Hold	4,846	–	–	﹤0.01%	2649
2022 Q1	$24K	Sell	4,846 -4,263	-47%	-$27.1K	﹤0.01%	2909
2021 Q4	$79K	Buy	+9,109	New	+$81.3K	﹤0.01%	2036
2021 Q3	–	Sell	-4,310	Closed	-$43.4K	–	6485
2021 Q2	$55K	Sell	4,310 -8,715	-67%	-$93.7K	﹤0.01%	2415
2021 Q1	$119K	Buy	+13,025	New	+$114K	0.01%	1640
2017 Q1	–	Sell	-50	Closed	-$2K	–	7363
2016 Q4	$2K	Hold	50	–	–	﹤0.01%	5745
2016 Q3	$3K	Hold	50	–	–	﹤0.01%	5485
2016 Q2	$3K	Buy	+50	New	+$8.23K	﹤0.01%	5460

Other funds holding ZVRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Cutler Group's ZVRA Position: Q1 2023 in Review

Cutler Group sold out of Zevra Therapeutics (ZVRA) in Q1 2023, closing a stake of 679 shares — an estimated $3K sold.

Cutler Group first reported a position in ZVRA in Q2 2016 and held it in 10 quarters. The position peaked at $119K in Q1 2021. 60 funds tracked by Wall St. Rank hold ZVRA as of Q1 2023.

Cutler Group reported no remaining Zevra Therapeutics position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 679 Zevra Therapeutics shares in Q1 2023, an estimated $3K.
Cutler Group first reported a position in Zevra Therapeutics in Q2 2016 and held it in 10 quarters.
Cutler Group's Zevra Therapeutics position peaked at $119K in Q1 2021.
60 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.